https://sputnikglobe.com/20220915/indian-pharma-industry-likely-to-reach-130bln-by-2030---report-1100818989.html
Indian Pharma Industry Likely to Reach $130Bln by 2030 - Report
Indian Pharma Industry Likely to Reach $130Bln by 2030 - Report
Sputnik International
India, whose pharma industry is the third largest in the world, supplies medicines to over 200 countries globally. With India becoming the fifth largest... 15.09.2022, Sputnik International
2022-09-15T14:53+0000
2022-09-15T14:53+0000
2022-09-15T14:53+0000
india
big pharma
big pharma
pharmaceuticals
pharmacies
pharmaceuticals
medicine
medicine
innovation
technology
https://cdn1.img.sputnikglobe.com/img/07e6/09/0f/1100822886_0:42:3147:1812_1920x0_80_0_0_93ea0cf2db73e4ccf68cf1cf4f7d9176.jpg
The Indian pharma industry, which is currently valued at $49 billion, is expected to reach $130 billion by 2030 and become the leading provider of medicines in the world, Indian Pharmaceutical Alliance (IPA) Secretary General, Sudarshan Jain told IANS on Thursday.Citing two big factors for the growing Indian pharma industry, Dr. Viranchi Shah, national president of the Indian Drug Manufacturers Association (IDMA), said that production-linked incentive schemes (PLIs) and cluster manufacturing are the key factors contributing to the sector's growth in India.Shah explained that with PLIs and cluster manufacturing, a large part of imported medicine and equipment will be manufactured locally, decreasing India's dependence on imports and guaranteeing national healthcare security.Other reasons, Shah said, India is moving from being a generic manufacturing giant to a value-added one are innovation, technology, and entrepreneurship, which will drive the country toward this goal.Big ChallengeRavi Uday Bhaskar, director general of Pharmexcil, said that although the future of the Indian pharma and allied industries is bright, there are several roadblocks to its growth. Bhaskar shares that any export will depend on import policies, which are different from country to country, and thus, there is a need to streamline the regulations. For this, an industry regulator understanding is important for growth, he said.
Sputnik International
feedback@sputniknews.com
+74956456601
MIA „Rosiya Segodnya“
2022
Sangeeta Yadav
https://cdn1.img.sputnikglobe.com/img/07e4/08/1b/1080292803_0:121:960:1081_100x100_80_0_0_7490b319dab9611e309056b177265184.jpg
Sangeeta Yadav
https://cdn1.img.sputnikglobe.com/img/07e4/08/1b/1080292803_0:121:960:1081_100x100_80_0_0_7490b319dab9611e309056b177265184.jpg
News
en_EN
Sputnik International
feedback@sputniknews.com
+74956456601
MIA „Rosiya Segodnya“
Sputnik International
feedback@sputniknews.com
+74956456601
MIA „Rosiya Segodnya“
Sangeeta Yadav
https://cdn1.img.sputnikglobe.com/img/07e4/08/1b/1080292803_0:121:960:1081_100x100_80_0_0_7490b319dab9611e309056b177265184.jpg
india, big pharma, big pharma, pharmaceuticals, pharmacies, pharmaceuticals, medicine, medicine, innovation, technology, medical equipment, medical facilities, medical study, medical issues
india, big pharma, big pharma, pharmaceuticals, pharmacies, pharmaceuticals, medicine, medicine, innovation, technology, medical equipment, medical facilities, medical study, medical issues
Indian Pharma Industry Likely to Reach $130Bln by 2030 - Report
India, whose pharma industry is the third largest in the world, supplies medicines to over 200 countries globally. With India becoming the fifth largest economy in the world, experts stress that it can make a global difference through innovation, self-dependence, diversifying the export market, and transforming the pharma industry.
The Indian pharma industry, which is currently valued at $49 billion, is expected to reach $130 billion by 2030 and become the leading provider of medicines in the world, Indian Pharmaceutical Alliance (IPA) Secretary General, Sudarshan Jain told IANS on Thursday.
Citing two big factors for the growing Indian pharma industry, Dr. Viranchi Shah, national president of the Indian Drug Manufacturers Association (IDMA), said that production-linked incentive schemes (PLIs) and cluster manufacturing are the key factors contributing to the sector's growth in India.
Shah explained that with PLIs and cluster manufacturing, a large part of imported medicine and equipment will be manufactured locally, decreasing India's dependence on imports and guaranteeing national healthcare security.
"When India completes its 100 years of independence, India in 2047 will be a $500 billion industry. PLI 1.0 and 2.0 are vital for India to achieve this goal," Shah said adding that his company is working with the Government of India on PLI 2.0.
Other reasons, Shah said, India is moving from being a generic manufacturing giant to a value-added one are innovation, technology, and entrepreneurship, which will drive the country toward this goal.
Ravi Uday Bhaskar, director general of Pharmexcil, said that although the future of the Indian pharma and allied industries is bright, there are several roadblocks to its growth.
Bhaskar shares that any export will depend on import policies, which are different from country to country, and thus, there is a need to streamline the regulations.
For this, an industry regulator understanding is important for growth, he said.
"Common regulatory standards like those in the European Union need to be worked out globally so that it is helpful for the pharma industry," Bhaskar explained.
